Talazoparib

About Nuvation Bio

Nuvation Bio is a mission-driven oncology company focused on developing next-generation therapies for cancers with high unmet need, aiming to improve efficacy and reduce side effects. A key inflection point was achieved in 2025 as the company transitioned to commercial-stage status, celebrating at the NYSE. Its strategy leverages founder David Hung's proven track record, a hybrid pipeline built on proprietary discovery and strategic acquisitions, and a global operational footprint. The company is now positioned to build a sustainable oncology franchise.

Therapeutic Areas